跳至主要内容
临床试验/2025-524327-53-00
2025-524327-53-00招募中4 期

Luteal phase support following letrozole treatment in women undergoing intrauterine insemination: a multicenter randomized trial

Region Midtjylland8 个研究点 分布在 1 个国家目标入组 690 人开始时间: 2026年2月2日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
690
试验地点
8
主要终点
Clinical pregnancy rate

研究概览

简要总结

To investigate if luteal phase support with a standard dose of vaginal progesterone increases the clinical pregnancy rates following mild ovarian stimulation with letrozole in infertile women undergoing IUI

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Age 18-37 years
  • Scheduled for intrauterine insemination with homologous or donor sperm
  • Undergoing mild ovarian stimulation with letrozole
  • Ability to provide written informed consent

排除标准

  • Age > 37 years
  • Anovulation due to hypogonadotropic hypogonadism
  • Known hypersensitivity to progesterone or to hard fat listed as an excipient in the Summary of Product Characteristics (SmPC) for Cyclogest.
  • Known or suspected progesterone-sensitive malignant tumours
  • Known missed abortion or ectopic pregnancy
  • Active arterial or venous thromboembolism, severe thrombophlebitis, or a history of these conditions
  • Severe hepatic dysfunction or liver disease
  • Inability to speak or understand Danish sufficiently to comprehend oral and written study information

研究组 & 干预措施

Cyclogest 400 mg vagitorier

Test

干预措施: Cyclogest 400 mg vagitorier (Drug)

结局指标

主要结局

Clinical pregnancy rate

Clinical pregnancy rate

次要结局

  • Live birth rate
  • Biochemical pregnancy rate
  • Early pregnancy loss
  • Fetal miscarriage
  • Perinatal outcomes: preterm birth, birth weight, congenital malformation, perinatal mortality
  • Obstetric outcomes: hypertensive disorders of pregnancy, gestational diabetes, postpartum hemorrhage and cesarean section
  • Hormone levels measured on the day of insemination, mid-luteal phase and ovulation trigger (optional)

研究者

发起方
Region Midtjylland
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Kirstine Kirkegaard

Scientific

Region Midtjylland

研究点 (8)

Loading locations...

相似试验